What is APVO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.00B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for APVO?

P/E (TTM) is n/a and 52-week range is $1.37 to $33.12 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s APVO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for APVO?

The company profile lists revenue (TTM) near $13M, net income (TTM) near $-2.89B, EPS (TTM) near $-51.32 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Aptevo Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Seattle, Washington, US, 1.3M shares outstanding, ISIN US03835L7029 when available from company profile and filing metadata.

Aptevo Therapeutics Inc

$APVO

Health Care · Biotechnology

IR Run Scenarios

$1.79

-0.56%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. The company is headquartered in Seattle, Washington and currently employs 33 full-time employees. The company went IPO on 2016-07-20. The firm has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The firm has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.

Employees

Website

aptevotherapeutics.com/

IPO

2016-07-20

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)